Adiponectin gene therapy
AssigneeApplied Genetic Technologies Corporation
InventorsSergei Zolotukhin, Michael D. Tennant
Life of this patent
Estimating the term…
Abstract
Adiponectin cDNA was cloned into AAV serotypes 1, 2, and 5-based expression vectors. Virions containing these vectors were administered to the livers of rat subjects via portal vein injection. A single injection of 6×1011 virions of the vector caused a sustained and statistically significant reduction in body weight of the treated animals compared to the control animals. This occurred in the absence of side effects. Compared to control animals, the subject rats also exhibited reduced adipose tissue mass, reduced appetite, improved insulin sensitivity, and improved glucose tolerance.
Claims37
A nucleic acid comprising:
- (A) a first AAV TR;
- (B) a second AAV TR;
- and
- (C) interposed between the first and second AAV TRs, a nucleotide sequence that encodes at least a portion of an adiponectin protein that has at least one functional activity of native adiponectin.
A method of modulating adiponectin protein levels in a subject, the method comprising administering to the subject a nucleic acid comprising:
- (A) a first AAV TR;
- (B) a second AAV TR;
- and
- (C) interposed between the first and second AAV TRs, a nucleotide sequence that encodes at least a portion of an adiponectin protein that has at least one functional activity of native adiponectin.
Dependencies are inferred from the claim text.